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Context After Roux-en-Y gastric bypass (RYGB) surgery, postprandial plasma glucagon 
concentrations have been reported to increase. This occurs despite concomitant improved 
glucose tolerance and increases in circulating plasma concentrations of insulin and the 
glucagon-inhibiting hormone glucagon-like peptide 1 (GLP-1). 
Objective Investigate whether RYGB-induced hyperglucagonemia may be derived from the 
gut. 
Design and setting Sub-study of a prospective cross-sectional study at a university hospital 
in Copenhagen, Denmark.  
Participants Morbidly obese individuals undergoing RYGB [n=8] with or without type 2 
diabetes.   
Interventions Three months before and after RYGB, participants underwent upper 
enteroscopy with gastrointestinal mucosal biopsy retrieval. Mixed meal tests were performed 
1 week and 3 months before and after RYGB. 
Main Outcome measures 29-amino acid glucagon concentrations in plasma and in mucosal 
gastrointestinal biopsies were assessed using mass spectrometry-validated immunoassays, 
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and a new monoclonal antibody reacting with immunoreactive glucagon was used for 
immunohistochemistry.  
Results We observed increased postprandial plasma concentrations of glucagon after RYGB. 
Small intestinal expression of the glucagon gene increased after surgery. Glucagon was 
identified in the small intestinal biopsies obtained after, but not before RYGB. 
Immunohistochemically, mucosal biopsies from the small intestine harbored cells co-staining 
for GLP-1 and immuno-reactive glucagon. 
Conclusions Increased concentrations of glucagon, estimated by two glucagon specific 
assays, were observed in small intestinal biopsies and postprandially in plasma after RYGB. 
The small intestine harbored cells immunohistochemically co-staining for GLP-1 and 
glucagon-like immunoreactivity after RYGB. These findings suggest that glucagon derived 
from small intestinal enteroendocrine L-cells may contribute to postprandial plasma 
concentrations of glucagon after RYGB.  
After RYGB surgery in obese individuals, we observed increased glucagon concentrations in 
postprandial plasma samples and gut biopsies, which also harbored cells IHS co-stained for GLP-1 
and glucagon. 
Introduction 
Roux-en-Y gastric bypass (RYGB) surgery has emerged as an effective treatment of obesity 
and type 2 diabetes1. The mechanisms underlying the antidiabetic effect of RYGB are 
complex and include increased insulin secretion stimulated by exaggerated postprandial 
secretion of the insulinotropic and glucagonostatic gut hormone, glucagon-like peptide 1 
(GLP-1)2. However, the surgical procedure has also been associated with postprandial 
hyperglucagonemia in several studies3–8. Postprandial hyperglucagonemia after RYGB is 
surprising and counterintuitive given the well-known RYGB-induced increases in circulating 
levels of insulin and GLP-1, which both would be expected to inhibit glucagon secretion9. A 
similar postprandial hyperglucagonemia has previously been observed in totally 
pancreatectomized patients after an oral glucose load, but not after iv administered glucose10. 
We therefore speculated that excessive postprandial plasma glucagon concentrations after 
RYGB might be gastrointestinally derived. We hypothesized that the postprandial increments 
in plasma glucagon concentrations after RYGB might reflect a disturbed processing of the 
common precursor for GLP-1 and glucagon, proglucagon, which is produced in the intestinal 
enteroendocrine L cells11. To test this hypothesis, we collected gastric and small intestinal 
mucosa biopsies by upper enteroscopy and performed mixed meal tests (MMTs) before and 
after surgery in eight individuals undergoing RYGB. We used mass spectrometry-validated 
immunoassays for glucagon quantification in plasma and mucosal biopsies and a new C-
terminal-specific monoclonal glucagon antibody for immunohistochemistry to elucidate 
whether the postprandial hyperglucagonemia observed after RYGB may reflect postoperative 
changes in proglucagon processing in the gastrointestinal mucosa. 
Research design and methods 
This study was a sub-study of a prospective observational study conducted in Denmark 
between December 2014 and December 2016. All participants gave written informed 
consent. The study was approved by the Municipal Ethical Committee of Copenhagen (reg. 
no. H-6-2014-047) performed in accordance with the Declaration of Helsinki II and 
registered at ClinicalTrials.gov (NCT03093298). 
Study participants  
Eight morbidly obese Caucasian individuals (sex: 2/6 (male/female); age [mean ± SD]: 48 ± 
5.6 years; body weight: 128 ± 21.8 kg; BMI: 42.2 ± 4.4 kg/m2) scheduled for laparoscopic 
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RYGB at a Danish public hospital, who met the study inclusion criteria (individuals assessed 
eligible for RYGB surgery, age ≥ 25 and ≤ 60 years) and exclusion criteria were included in 
the study. A full list of inclusion and exclusion criteria can be found at ClinicalTrials.gov 
(trial record NCT03093298). At inclusion, three of the participants were diagnosed with type 
2 diabetes and five had HbA1c < 48 mmol/mol (6.5%). The patients with type 2 diabetes were 
all on metformin monotherapy, which was paused for seven days prior to MMTs performed 
before RYGB and discontinued at the day of surgery. All participants completed a 
preoperative diet-induced body weight loss of at least 8%, as required by health care 
authorities in Denmark.  
Surgery was performed using a standard laparoscopic RYGB technique12 resulting in a 
gastric pouch with a volume of ~30 mL, a ~150 cm alimentary limb and a ~75 cm 
biliopancreatic limb (Fig. 1). None of the participants experienced complications 
perioperatively or during the following three postoperative months.  
Experimental procedures 
The participants were examined over a total of 6 experimental days. Identical MMTs were 
performed before the preoperative diet-induced weight loss program was initiated ~3 months 
(-3mo) and ~1 week preoperatively (-1wk), ~1 week and ~3 months postoperatively (+1wk 
and +3mo, respectively). In addition, an upper enteroscopy with biopsy retrieval was 
performed at ~3 months preoperatively and repeated ~3 months postoperatively. 
Liquid mixed meal tests.  
Each participant arrived at the research facility after 10 hours of fasting and abstinence from 
tobacco and alcohol as well as strenuous physical activity. Body weight was recorded, and 
the participant was placed in a hospital bed in a 45° recumbent position. For sampling of 
blood, a catheter was inserted into a cubital vein of a forearm wrapped in a heating pad. At 
time 0 min, the participants started ingesting a liquid mixed meal consisting of 200 mL 
Nutridrink [300 kcal, carbohydrate (50 E%), protein (15 E%), fat (35 E%), Nutricia 
Nutridrink, Allerød, Denmark] + 30 mL of water with 1,500 mg of dissolved acetaminophen 
(Pinex®, Actavis, Søborg, Denmark) (for evaluation of gastric emptying). The meal was 
ingested at an even rate over a 30-minute period at all MMT study days to avoid dumping 
symptoms after RYGB13. Blood was drawn before (time 0 min) and at time points 30, 60, 120 
and 240 min. The blood was distributed in chilled tubes and centrifuged. Plasma/serum was 
either analyzed immediately (glucose) or stored at -80°C until analysis (C-peptide, insulin, 
glucagon and gut hormones).  
Enteroscopy with biopsy retrieval.  
Gastrointestinal mucosa biopsies were obtained during propofol sedation using a pediatric 
colonoscope (PCF-Q180AL, Olympus, Tokyo, Japan). An illustration of the anatomy before 
and after surgery with indications of biopsy sites is given in Fig. 1. Before RYGB, the 
enteroscope was introduced 120 cm from cavum oris (without curving in the stomach). Then, 
using a standard forceps, biopsies were sampled from the small intestine at the expected site 
of the entero-entero anastomosis (X) and from the proximal part of the lesser curvature of the 
stomach (G1), which is preserved after surgery. Approximately three months after RYGB, 
biopsies were sampled from the remnant gastric pouch (G2), the alimentary limb (A), the 
biliopancreatic limb (B) and the common channel (C), respectively (Fig. 1). Eight biopsies 
were sampled at each location and were snap frozen and subsequently stored at -80°C until 
analysis or placed in formaldehyde 4% (for immunohistochemical staining) and transferred to 
ethanol after 24 hours and stored refrigerated. 
Biochemical analyses 
Blood for bedside measurements was collected in Eppendorf tubes containing sodium 
fluoride and centrifuged for 30 seconds at 6,720 g. Plasma glucose concentrations were 
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measured using the glucose oxidase method (YSI 2300 STAT plus analyzer, YSI Inc., 
Yellow Springs, OH, USA). Blood for plasma acetaminophen measurement was collected in 
tubes added lithium-heparin (Vacuette, Greiner Bio-One GmbH, Frickenhausen, Germany). 
Blood for serum insulin and C-peptide concentrations was collected in tubes added clot 
activator (Vacuette, Greiner Bio-One GmbH, Frickenhausen, Germany) and kept at room 
temperature until complete coagulation. Blood for analyses of gut hormones was collected in 
iced P800 tubes (BD Biosciences, San Jose, CA, USA) added a proprietary cocktail of 
protease, esterase and dipeptidyl peptidase 4 inhibitors. Plasma and serum were separated 
from blood cells and platelets by centrifugation at 2,876 g for 15 minutes at -4°C (Hettich 
ROTINA 420R, Merck, Tuttlingen, Germany) and was kept at -80°C until analysis. Plasma 
acetaminophen was measured using dry chemistry technology (Vitros 5.1 FS, Ortho-Clinical 
Diagnostics, Allerød, Denmark). Serum insulin and C-peptide were quantified by routine 
chemiluminescence immunoassays using the ADVIA Centaur XP analyzer (Siemens 
Healthcare, Ballerup, Denmark). Total plasma glucose-dependent insulinotropic peptide 
(GIP), active GLP-1 (GLP-1(7-36)NH2 + GLP-1(7-37)glycine) and total peptide YY (PYY) 
concentrations were measured using a custom-made ELISA (Meso Scale Discovery, N45ZA, 
Gaithersburg, MD, USA). Plasma samples were undiluted, run in duplicates and analyzed on 
a Meso Scale Discovery MESO QuickPlex SQ 120 plate reader (Meso Scale Discovery, 
Rockville, MD, USA) according to manufacturer’s protocol. Extractable GLP-1 
concentrations in the intestinal biopsies were measured using a sandwich ELISA, which 
equally detects GLP-1(7-36)NH2 and GLP-1(9-36)NH2, as previously described14. Glucagon 
concentrations (both plasma and intestinal) were measured using an in-house RIA based on a 
C-terminal-wrapping antibody (code 4305) and a sandwich ELISA (Mercodia A/S, Uppsala, 
Sweden) based on N and C-terminal-wrapping monoclonal antibodies as described 
previously15. N-terminally elongated glucagon (proglucagon 1-61), oxyntomodulin and 
glicentin were measured as previously described16,17.  
mRNA sequencing of gut biopsies.  
mRNA sequencing (mRNA-seq) of small intestinal mucosa tissue embedded in Tissue-Tek® 
O.C.T. Compound (Sakura® Finetek, Torrance, CA, USA) was performed in biopsies 
obtained before and after RYGB. Total RNA from each biopsy was purified using 
NucleoSpin® RNA Plus (Macherey-Nagel, Düren, Germany). The quantity of the purified 
RNA was measured using Qubit® RNA BR Assay Kit (Thermo Fisher Scientific, Waltham, 
MA, USA). The quality of purified RNA was determined with a Bioanalyzer using Agilent 
RNA 6000 Nano Kit (Agilent Technology, Waldbrönn, Germany). Subsequently, cDNA 
library preparation with 25-100 ng of purified RNA sample using TruSeq® Stranded mRNA 
Library Prep Kit for NeoPrep™ (Illumina, San Diego, CA, USA) was prepared. The 
sequencing of cDNA libraries was performed with NS® 500 high Output Kit v2 (75 cycles) 
(Illumina, San Diego, CA, USA) on a NextSeq 500 platform. The gene expression level is 
displayed as reads per kilobase million (RPKM), thus quantifying gene expression from 
mRNA sequencing data by normalizing for total read length and the number of sequencing 
reads. 
Peptide extraction.  
Snap-frozen mucosal tissue was weighed and subsequently homogenized in 1% 
trifluoroacetic acid (cat. no. TS-28904, Thermo Fisher Scientific, Waltham, MA, USA) with 
a 5 mm-steel bead and a bead mill (TissueLyzer, Qiagen Instruments AG, Hombrechtikon, 
Switzerland) at 30 Hz for 4 × 2 min. Next, samples were left to stand one hour at room 
temperature and cleared by centrifugation (3,300 g, 10 minutes, room temperature). Total 
protein concentration was estimated using a bicinchoninic acid assay (cat. no. 23225, Fischer 
Scientific, Roskilde, Denmark). Extracts were then purified using Sep-Pak pH resistant tc18 
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cartridges (cat. no. WAT036810, Waters, Milford, MA, USA) and peptides were eluted in 
70% ethanol containing 0.1% trifluoroacetic acid and dried under a gentle stream of 
compressed air overnight. Samples were reconstituted in assay buffer before analysis (100 
mmol/l TRIS buffer (cat. no. T-3253 and T-1503, Merck KGaA, Darmstadt, Germany) 
supplemented with 0.1% (w/v) human serum albumin (cat. no. 12666, Merck KGaA, 
Darmstadt, Germany), 20 mmol/L EDTA and 0.6 mmol/L Thiomersal (cat. no. T-5125, 
Sigma Chemical Co., St. Louis, MO, USA) (pH 8.5). More details are described elsewhere18.  
Immunohistochemical staining  
Double immunohistochemical staining of gastrointestinal biopsies was performed using a 
custom-made monoclonal mouse C-terminal-wrapping anti-glucagon mouse antibody (20-
7060-01/E6Al 1K, 1:5000, Mercodia A/S, Uppsala, Sweden) and a previously validated 
rabbit C-terminal (amide requiring) GLP-1 antibody (in-house 89390, 1:1000, University of 
Copenhagen, Denmark19). The specificity of the glucagon antibody was tested in archival 
sections of human pancreas by addition of 1 µM glucagon or a C-terminal fragment of 
oxyntomodulin (CKMNTKRNRNNIA, GenScript, Piscataway Township, NJ, USA) to the 
diluted antibody before double immunohistochemical staining. In these sections, staining was 
totally abolished with glucagon, but unaffected by the oxyntomodulin fragment (data not 
shown). For immunohistochemical double-stainings, 5 µm sections of all intestinal biopsies 
were dewaxed and subjected to microwave antigen retrieval with EGTA buffer, pH 9, for 15 
minutes. Sections were then preincubated 15 minutes with 2% BSA and subsequently 
incubated overnight at 4°C with the primary antibodies. Double-staining for glucagon and 
GLP-1 was performed using the glucagon antibody anti-glucagon 1:5000 (mouse, Mercodia 
A/S, Uppsala, Sweden) and the anti-GLP-1 1:1000. Immunohistochemical double-staining 
for glucagon and prohormone convertase 2 (PC2) was performed using the glucagon 
antibody 1:5000 and a human specific PC2 antibody (rabbit, ALX-210-529-R100, Enzo Life 
Sciences, Farmingdale, NY, USA) 1:1000. The sections were washed and incubated with a 
mixture of Alexa488 goat anti-rabbit antibody (1:500, Life Technologies, Carlsbad, CA, 
USA) and Alexa568 donkey anti-mouse (1:500, 175700, Abcam, Cambridge, England), 
washed in buffer and cover-slipped. The stained sections were examined using an Axioscope 
2 plus microscope (Zeiss, Jena, Germany). Images were taken using CoolSNAP camera 
(Photometrics, Tucson, AZ, USA). 
Calculations and statistical analysis 
Area under the curve (AUC) was calculated by the trapezoidal rule and presented as total and 
baseline-subtracted AUC (bsAUC). Due to a substantial number of zero-concentration for 
biopsy samples, all comparisons between gastric samples (G1 and G2) and comparisons 
between intestinal samples (X, A, B and C) for RIA-measured glucagon and proglucagon 1-
61 were analysed using McNemars test for dichotomized data (concentration = 0 vs. >0). For 
plasma/serum analyses, basal, Cmax (maximum concentration (peak) during 4-hour MMT), 
Tmax (time-to-peak), AUC and bsAUC values were evaluated.  Summary statistics were 
reported as mean ± SD for normally distributed variables, skew distributions were log-
transformed prior to analysis and presented as median (IQR). Changes in outcome between 
the MMT study days were assessed by linear mixed model analyses20. An unstructured 
covariance was assumed. Goodness of fit was assessed by residual diagnostics. Due to the 
large number of tests carried out, all P values were corrected for multiple testing using the 
Benjamini and Hochberg procedure21. A standard cut-off for the false discovery rate at 0.1 
was applied (i.e. adjusted P values of <0.10 were considered statistically significant, which 
limits the rate of false-positives among the reported findings to one in ten). All data were 
statistically processed using SAS software version 9.1 (SAS Institute, Cary, NC, USA). 
GraphPad Prism Software version 7 (La Jolla, CA, USA) was used to create graphs.  
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Results 
Clinical characteristics of study participants before and after RYGB 
The mean weight loss during the preoperative diet-induced weight loss period was 8.4 ± 3.4 
kg, and 3 months postoperatively, the participants had lost another 14.6 ± 5.2 kg, 
corresponding to decreases in BMI of 2.7 ± 0.9 kg/m2 and 4.7 ± 1.4 kg/m2, respectively. 
After surgery, HbA1c, insulin resistance and sensitivity and cholesterols improved 
significantly (figshare.com). 
Increased secretion of gut hormones and glucagon after RYGB 
RYGB increased the acetaminophen absorption rate, a proxy for the transit of the meal to the 
small intestine (Fig. 2A). As expected, postprandial plasma glucose profiles changed 1 week 
after RYGB (Fig. 2B) with reduced time-to-peak (Tmax) and lower 120 min plasma glucose 
concentrations (Table 1). The 3-month postoperative plasma glucose profiles were similar to 
the 1-week profiles (Fig. 2B). 
The postprandial serum excursions of insulin and C-peptide also changed as a result of 
surgery (Fig. 2C, Fig. 2D). Three months after RYGB, basal insulin and C-peptide decreased, 
and the peak concentrations of insulin nearly doubled postoperatively compared to 
preoperative concentrations (Fig. 2C, Table 1). 
For ELISA-measured glucagon, the postprandial peak concentration (Fig. 3A, Table 1) 
and the initial 120 min postprandial response (bsAUC0-120min) were increased 1 week after 
RYGB. The 120 min postprandial response (bsAUC0-120min) dropped 3 months after RYGB, 
however, was elevated compared to the preoperative postprandial responses (Fig. 3A, Table 
1). Similar results were found using a validated C-terminal specific glucagon RIA 
(figshare.com). The basal and peak concentrations and the postprandial response (AUC) of 
proglucagon 1-61 increased 1 week after RYGB compared to preoperative concentrations and 
remained elevated 3 months after RYGB compared to preoperatively (Fig. 3B, Table 1). 
Postprandial plasma concentrations of active GLP-1 increased 1 week after RYGB 
compared to 3 months preoperatively with a nearly 12-fold increase in peak concentration, 
and ~5.4 and ~14 fold greater AUC and bsAUC, respectively (Fig. 3C, Table 1). Three 
months postoperatively, the postprandial GLP-1 responses remained elevated compared to 
preoperatively (Fig. 3C, Table 1).  
The basal and peak concentrations and postprandial responses of plasma glicentin and 
oxyntomodulin increased 1 week after RYGB (Fig. 3D, Fig. 3E, Table 1). These parameters 
decreased somewhat 3 months after RYGB, yet remained elevated compared to 
preoperatively (Fig. 3D, Fig. 3E, Table 1). The peak and postprandial levels of plasma PYY 
increased 1 week after RYGB compared to 3 months preoperatively and remained elevated 3 
months after surgery compared to preoperatively (Fig. 3F, Table 1). 
One week after RYGB, the time-to-peak decreased for GIP compared to preoperative 
levels. The postprandial GIP responses decreased 3 months after RYGB compared to 3 
months preoperatively (Fig. 4, Table 1). 
Glucagon in gut biopsies after RYGB  
The expression of the glucagon gene (GCG) (encoding proglucagon) increased in the 
intestinal mucosa after RYGB in the biliopancreatic limb (Fig. 5A). The expression of the 
PCSK2 gene (encoding PC2, which in the pancreatic alpha cells cleaves proglucagon to 
glucagon) was very low in intestinal mucosa and did not change after surgery (Fig. 5B). 
Before RYGB surgery, glucagon was not detectable in six of the eight biopsies from the 
gastric mucosa and in five of the eight biopsies from the small intestinal mucosa, and values 
below the limit of detection (1 pmol/g) were obtained in the remaining biopsies (Fig. 5C). 
After RYGB, glucagon was not detectable in gastric mucosa biopsies, but increased 
concentrations were identified in the mucosa biopsies from the alimentary and biliopancreatic 
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limb as well as the common channel (Fig. 5C). Similar data were observed using a C-
terminal-specific glucagon RIA (figshare.com). Proglucagon 1-61 was undetectable in gastric 
as well as intestinal mucosa biopsies before RYGB, but concentrations were detectable in the 
small intestine after surgery (Fig. 5D). GLP-1 was not above analytical detection limits in 
gastric biopsies before and after RYGB (Fig. 5E), whereas intestinal GLP-1 was detected 
before RYGB and the concentrations increased after surgery (Fig. 5E).  
Glucagon localized to GLP-1-producing cells after RYGB 
GLP-1-producing L cells were found in biopsies from the small intestine, and the majority 
also expressed glucagon as determined using the specific C-terminal monoclonal glucagon 
antibody. A few cells were only GLP-1 immunoreactive, but no cells were only glucagon 
immunoreactive (Fig. 6). There were no cells displaying immunoreactivity for glucagon or 
GLP-1 in the gastric biopsies (data not shown). Also, some cells were displaying 
immunoreactivity for PC2 in the small intestinal biopsies but not for both PC2 and glucagon 
(figshare.com). 
Discussion 
This study suggests that fully processed glucagon 1-29 may be generated by GLP-1-
producing enteroendocrine L cells in the proximal part of the small intestine following 
RYGB surgery in humans. 
The hypothesis of extrapancreatic glucagon in humans has been supported by findings of 
plasma glucagon in totally pancreatectomized patients22. The findings were replicated using a 
RIA directed against the free C-terminus of glucagon, a region which is only exposed after 
cleavage of proglucagon at the dibasic consensus site (residues 62 and 63 in proglucagon), 
which in the pancreas is cleaved by PC222. However, such assays will also react with N-
terminally elongated glucagon isoforms (e.g. proglucagon 1-61). New sandwich ELISAs 
targeting simultaneously the C and N-termini of the peptide hormones have been developed, 
minimizing potential ‘cross-reactivities’ with such elongated forms reacting with the C-
terminal assays15. A recent study, using a mass-spectrometry-validated sandwich ELISA, 
confirmed the presence of circulating glucagon 1-29 after total pancreatectomy in man10. 
Common for these patients and the RYGB-operated individuals included in the present study, 
is the surgery-induced gastrointestinal rearrangement involving removal of the pyloric 
sphincter leading to rapid delivery of ingested nutrients and, hence, altered stimulation of 
enteroendocrine cells in the small intestine. In the present study, we observed an increase of 
proglucagon-derivatives (GLP-1, glicentin, oxyntomodulin and proglucagon 1-61 in addition 
to glucagon 1-29) in plasma, using newly developed and mass-spectrometry-validated 
sandwich ELISAs15. Roberts et al. were unable to detect increased glucagon secretion in 
plasma of lean individuals undergoing gastrectomy when using liquid chromatography-mass 
spectrometry (LCMS)23. Roberts et al. proposed that elevated plasma levels of glucagon after 
RYGB surgery may be due to cross-reactivity with other proglucagon-like molecules such as 
glicentin23. We therefore used two extensively evaluated antibody-based methods, RIA and 
ELISA10,15, with a documented lack of cross reaction with these molecular species. The 
results obtained with the ELISA were closely mirrored by results obtained with the C-
terminally directed glucagon RIA. In addition, we included immunohistochemistry using a 
new monoclonal antibody reacting exclusively with the C-terminus of the glucagon molecule 
(and therefore capable of reacting only with molecules exposing this sequence, i.e. fully 
processed glucagon 1-29 or proglucagon 1-61) – and found positive immunoreactivity in 
many L cells, indicating that cleavage leading to the formation of one or both of these two 
moieties did occur in the GLP-1-producing cells identified in the biopsies. 
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An important limitation to the study is the small number of participants, which limits the 
statistical power. Regarding the meal-stimulated glucagon response in plasma, the 0-120 min 
of the bsAUC for glucagon was evaluated (in addition to the 0-240 min) because the meal-
induced response had a duration corresponding to this period (a complete return to basal 
levels was reached at 120 min on all days). The postprandial glucagon response increased 
numerically after RYGB compared to before surgery (for bsAUC at time 0-240 min and 0-
120 min). Increasing postprandial plasma concentrations of glucagon after RYGB are 
surprising in view of the concomitant, high concentrations of insulin and GLP-1, both known 
to inhibit glucagon secretion. Another study limitation is the mix of participants with and 
without type 2 diabetes in small groups of n = 3 (T2D) vs. n = 5 (NGT), respectively. 
Statistical analysis of such small groups is not meaningful and was therefore not performed. 
Nevertheless, we observed a trend for higher concentrations of glucagon, proglucagon 1-61 
and GLP-1 in the biopsies of the NGT group.  
GLP-1 and glucagon are both processed from the GCG gene product, proglucagon (Fig. 
7). The proglucagon-processing PCs and their peptide products are traditionally considered 
tissue-specific (i.e. PC1/3 occurs in and acts on proglucagon in gut and brain forming GLP-1, 
while PC2 occurs in and acts on proglucagon in pancreatic alpha cells forming glucagon). 
However, the absolute tissue specificity of proglucagon processing has been challenged by 
previous findings of intestinal PCSK2 mRNA expression and PC2-positive cells in human 
gut biopsies 24,25. In addition, the two processing enzymes may have overlapping specificities 
26
. From these data, we suggest that in the intestine, processing of proglucagon to glucagon 
may therefore not be PC2-dependent and may occur on the basis of unspecific processing of 
proglucagon from PC1/3 or other prohormone convertases.  
Contradictory results have been found regarding presence of gastric glucagon in humans. 
Ravazzola et al.27 identified glucagon-positive cells in the fetal human stomach that showed 
ultrastructural features consistent with pancreatic alpha cells, whereas Holst et al. were 
unable to detect glucagon in gastric mucosal biopsies from adult humans28. In the gastric 
mucosa biopsies from the present study, glucagon concentrations were almost undetectable, 
and we saw no signs of increases in glucagon content following RYGB. Furthermore, no 
glucagon immunoreactivity was identified by immunohistochemistry in the gastric biopsies 
(data not shown). Accordingly, we find it unlikely that the stomach contributes to RYGB-
induced hyperglucagonemia. 
Although we cannot exclude that the increase in plasma glucagon may be of pancreatic 
origin (perhaps via accelerated amino acid absorption), our findings do support a potential 
involvement of the intestinal tract in the postprandial hyperglucagonemia observed after 
RYGB surgery and - possibly - other conditions characterized by postprandial 
hyperglucagonemia. It is of importance to recognize the limitations of antibody-based 
methods as used in this study as they may suffer from inaccuracy and therefore future studies 
combining antibody-dependent and independent approaches are warranted. Whether 
increased circulating glucagon after RYGB surgery has any physiological implications (e.g. 
protection from hyperinsulinemic hypoglycemia) remains to be established.  
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Figure 1. Illustration of the gastrointestinal anatomy before (left) and after (right) RYGB 
with black circles indicating biopsy sites (A, alimentary limb; B, biliopancreatic limb; C, 
common channel; G1, proximally at the lesser curvature of the stomach; G2, remnant gastric 
pouch; X, the expected site of entero-entero anastomosis (black line)). RPKM, reads per 
kilobase million 
Figure 2. Plasma responses for glucose, insulin and C-peptide . Plasma/serum excursions 
for acetaminophen (A), glucose (B), insulin (C) and C-peptide (D) from 4-hour liquid mixed 
meal tests (MMT) performed in participants (n = 8) before (MMT -3mo, full black circles) 
and after (MMT -1wk, open black circles) a diet-induced weight loss and ~1 week (MMT 
+1wk, full blue triangles) and 3 months (MMT +3mo, open blue triangles) after RYGB 
surgery. Data are mean ± SD. 
Figure 3. Plasma responses for glucagon, proglucagon 1-61, GLP-1, oxyntomodulin, 
glicentin and PYY. Plasma responses of glucagon (A), proglucagon 1-61 (B), active 
glucagon-like peptide 1 (GLP-1) (C ), oxyntomodulin (D), glicentin (E) and total peptide YY 
(PYY) (F) from 4-hour liquid mixed meal test (MMT) performed in participants (n = 8) 
before (MMT -3mo, full black circles) and after (MMT -1wk, open black circles) a diet-
induced weight loss and ~1 week (MMT +1wk, full blue triangles) and 3 months (MMT 
+3mo, open blue triangles) after RYGB surgery. Data are mean ± SD for normally distributed 
variables (A, B, C, D, E), geometric mean ± 95% CI for skewed distributions (F). 
Figure 4. Plasma response for GIP. Plasma response for total glucose-dependent 
insulinotropic polypeptide (GIP) from 4-hour liquid mixed meal test (MMT) performed in 
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participants (n = 8) before (MMT -3mo, full black circles) and after (MMT -1wk, open black 
circles) a diet-induced weight loss and ~1 week (MMT +1wk, full blue triangles) and 3 
months (MMT +3mo, open blue triangles) after RYGB surgery. Data are mean geometric 
mean ± 95% CI for skewed distributions. 
Figure 5. Expression level of GCG and PCSK2, and concentrations of glucagon, 
proglucagon 1-61 and GLP-1 in gut biopsies. Gene expression level of the glucagon gene 
(GCG) (A) and the gene encoding prohormone convertase (PCSK2) (B) and concentrations 
(pmol/g mucosal tissue) of glucagon (C), proglucagon 1-61 (D) and glucagon-like peptide 1 
(GLP-1) measured with ELISAs (E), in biopsies sampled before (Pre G1, Pre X) and after 
(Post G2, Post A, Post B, Post C) Roux-en Y gastric bypass (RYGB) surgery in individuals 
with (n = 3) and without type 2 diabetes (n = 5). Data are shown as univariate scatter plots 
with median (horizontal line). Significant differences (false discovery rate-adjusted p < 0.1) 
between biopsy sites are indicated by letters above data plots. F illustrates the gastrointestinal 
anatomy before (left) and after (right) RYGB with black circles indicating biopsy sites (A, 
alimentary limb; B, biliopancreatic limb; C, common channel; G1, proximally at the lesser 
curvature of the stomach; G2, remnant gastric pouch; X, the expected site of entero-entero 
anastomosis (black line)). RPKM, reads per kilobase million 
Figure 6. Co-localization of glucagon and GLP-1 in the small intestine. 
Immunohistochemical staining of two small intestinal biopsies after RYGB surgery showing 
glucagon-like peptide 1 (GLP-1) (green) (A, D) and glucagon (red) (B, E) and co-localization 
of glucagon and GLP-1 (yellow) (C, F). Arrows indicate GLP-1-positive cells (not glucagon-
positive). 
Figure 7. Differential processing of proglucagon and antibodies for analyses. Differential 
processing of proglucagon by prohormone convertase (PC) 2 and PC1/3, respectively, and 
antibodies (AB) used in specific analyses. The numbers refer to amino acid positions in the 
160-amino acid proglucagon sequence. GLP-1, glucagon-like peptide 1; GLP-2, glucagon-
like peptide 2; GRPP, glicentin-related pancreatic polypeptide; IP-1, intervening peptide 1; 
IP-2, intervening peptide 2 
Table 1. Plasma acetaminophen, glucose and hormonal responses 
    
Diet-induced weight loss period (before 
RYGB) Surgery-induced weight loss period (after RYGB) 
 MMT -3mo (1) MMT -1wk (2) MMT +1wk (3) MMT +3mo (4) 
Acetaminophen     
 Basal (mmol/L) 4.00 ± 2.60 5.86 ± 0.27 7.25 ± 9.38 4.57 ± 2.13 
 Cmax (mmol/L) 67.9 ± 11.63,4 74.0 ± 18.63,4 136.0 ± 38.81,2,4 146 ± 33.51,2,3 
 Tmax (min) 97.5 ± 29.03,4 94.3 ± 29.73,4 30.0 ± 0.001,2 30.0 ± 0.001,2 
 AUC (mmol/L × min) 10.6 ± 2.073,4 11.9 ± 2.671,3,4 15.0 ± 3.931,2,4 17.3 ± 4.531,2,3 
 bsAUC (mmol/L × min) 9.57 ± 1.933,4 10.5 ± 2.483,4 13.3 ± 4.601,2,4 16.2 ± 4.411,2,3 
Glucose     
 Basal (mmol/L) 7.06 ± 2.58 5.98 ± 1.16 5.66 ± 0.76 5.25 ± 0.68 
 120-min' (mmol/L) 8.78 ± 3.003,4 7.35 ± 1.593,4 5.46 ± 1.291,2,4 5.03 ± 1.131,2,3 
 Cmax (mmol/L) 9.61 ± 2.89 8.54 ± 2.76 9.31 ± 2.04 9.40 ± 1.62 
 Tmax (min) 97.5 ± 29.03,4 77.1 ± 27.13,4 41.3 ± 14.51,2 37.5 ± 13.01,2 
 AUC (mmol/L × min) 1900 ± 597 1660 ± 392 1536 ± 272 1464 ± 232 
 bsAUC (mmol/L × min) 205 ± 125 225 ± 133 178 ± 155 204 ± 77 
Insulin     
 Basal (pmol/L) 209 ± 1344 115 ± 47 90.5 ± 18.74 62.9 ± 19.61,3 
 Cmax (pmol/L) 580 ± 2364 572 ± 2783,4 1194 ± 6202 1039 ± 3601,2 
 Tmax (min) 60.0 ± 26.0 64.3 ± 25.04 41.3 ± 14.5 45.0 ± 15.02 
 AUC (nmol/L × min) 75.8 ± 19.9 71.1 ± 22.3 87.6 ± 44.6 69.6 ± 27.3 
 bsAUC (nmol/L × min) 25.6 ± 32.4 43.6 ± 19.4 65.9 ± 42.8 55.3 ± 26.2 
C-peptide     
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 Basal (pmol/L) 1114 ± 5364 797 ± 2364 805 ± 2694 578 ± 2281,2,3
 
 Cmax (pmol/L) 2171 (1919;2517)3 1841 (1592;2489)3 3343 (2210;4461)1,2 2590 (2008;3943) 
 Tmax (min) 90 (60;120)3,4 60 (60;90)3,4 60 (53;60)1,2 60 (30;60)1,2 
 AUC (nmol/L × min) 373 ± 49 349 ± 90 436 ± 1634 362 ± 1333 
 bsAUC (nmol/L × min) 106 ± 107 157 ± 52 243 ± 117 223 ±85 
Glucagon     
 Basal (pmol/L) 6.25 ± 2.28 6.14 ± 2.17 5.13 ± 1.05 5.75 ± 0.97 
 Cmax (pmol/L) 7.88 ± 2.373 8.00 ± 1.313 10.5 ± 2.11,2 9.25 ± 1.64 
 Tmax (min) 26.3 ± 18.0 34.3 ± 19.2 45.0 ± 15.0 37.5 ± 13.0 
 AUC (pmol/L × min) 1284 ± 404 1378 ± 334 1414 ± 343 1399 ± 257 
 bsAUC (pmol/L × min) -216 ± 223 -96.4 ± 435 184 ± 302 18.8 ± 194 
 bsAUC0-120min (pmol/L x  
min) 
9.38 ± 1413 57.9 ± 174 319 ± 1471,4 161 ± 1183 
Proglucagon 1-61     
 Basal (pmol/L) 3.14 ± 0.603,4 3.29 ± 0.704 4.75 ± 1.791 5.63 ± 1.321,2 
 Cmax (pmol/L) 5.29 ± 1.163,4 4.86 ± 0.643,4 8.13 ± 2.091,2 9.00 ± 2.181,2 
 Tmax (min) 71.3 ± 29.8 42.9 ± 21.93 120 ± 732 90.0 ± 65.4 
 AUC (pmol/L × min) 1009 ± 2584 930 ± 1933,4 1530 ± 4112 1641 ± 3461,2 
 bsAUC (pmol/L × min) 255 ± 208 141 ± 226 390 ± 235 291 ± 287 
GLP-1     
 Basal (pmol/L) 0.49 ± 0.18 0.53 ± 0.10 0.60 ± 0.26 0.55 ± 0.16 
 Cmax (pmol/L) 1.84 ± 0.853,4 1.86 ± 0.663,4 17.8 ± 8.81,2 20.9 ± 9.01,2 
 Tmax (min) 52.5 ± 29.03 42.9 ± 14.8 45.0 ± 15.01,4 30.0 ± 0.03 
 AUC (pmol/L × min) 219 (168;300)3,4 207 (186;259)3,4 1393 (830;1852)1,2 1264 (891;1449)1,2 
 bsAUC (pmol/L × min) 107 (66;188)3,4 87.8 (53.3;121.4)3,4 1227 (594;1727)1,2 1096 (730;1335)1,2 
Glicentin     
 Basal (pmol/L) 36.6 ± 10.13 37.6 ± 6.903 60.5 ± 16.72,4 44.8 ± 14.63 
 Cmax (pmol/L) 65.8 ± 10.43,4 61.7 ± 10.03,4 232 ± 44.01,2,4 188 ± 54.01,2,3 
 Tmax (min) 97.5 ± 29.04 107 ± 64.0 67.5 ± 19.8 56.3 ± 9.901 
 AUC (nmol/L × min) 13.3 ± 2.403,4 12.5 ± 2.103,4 34.2 ± 9.101,2,4 24.9 ± 7.301,2,3 
 bsAUC (nmol/L × min) 4.66 (3.62;5.09)3,4 2.88 (2.50;3.77)3,4 15.3 (13.2;20.8)1,2,4 10.0 (9.00;15.5)1,2,3 
Oxyntomodulin     
 Basal (pmol/L) 14.5 ± 4.103,4 15.3 ± 3.003 23.3 ± 8.001,2,4 19.4 ± 6.401,3 
 Cmax (pmol/L) 25.1 ± 4.703,4 24.4 ± 3.503,4 89.9 ± 23.81,2,4 69.8 ± 17.41,2,3 
 Tmax (min) 97.5 ± 29.0 81.4 ± 34.8 67.5 ± 19.8 60.0 ± 0.00 
 AUC (nmol/L × min) 5.13 ± 0.963,4 4.99 ± 0.753,4 12.7 ± 3.501,2,4 10.1 ± 2.901,2,3 
 bsAUC (nmol/L × min) 1.55 (1.16;1.91) 1.26 (0.81;1.78) 5.72 (4.19;8.25) 3.65 (3.43;6.29) 
PYY     
 Basal (pmol/L) 7.31 (5.26;9.92) 5.13 (4.87;10.57) 5.80 (5.11;8.86) 6.58 (5.57;10.45) 
 Cmax (pmol/L) 11.1 (10.2;2019.8)3,4 12.1 (11.5;27.4)3,4 45.3 (35.8;74.1)1,2 47 (35;55)1,2 
 Tmax (min) 90 (60;120) 60 (45;60) 60 (60;60) 60 (60;60) 
 AUC (pmol/L × min) 3182 ± 19003,4 3396 ± 1689 7811 ± 41691 7958 ± 49651 
 bsAUC (pmol/L × min) 1085 ± 13403,4 1087 ± 14643,4 6009 ± 38101,2 5672 ± 38681,2 
GIP     
 Basal (pmol/L) 15 (12;23) 13 (10;15) 11 (9;11) 14 (13;16) 
 Cmax (pmol/L) 107 (86;164) 151 (101;221) 148 (132;229) 147 (97;320) 
 Tmax (min) 60 (60;75)3,4 60 (45;60)3,4 45 (30;60)1,2 30 (30;30)1,2 
 AUC (pmol/L × min) 68 (61;96)4 87 (77;107) 69 (59;103) 63 (48;110)1 
 bsAUC (pmol/L × min) 55 (37;75) 75 (62;89) 57 (47;89) 46 (34;91) 
Fasting and postprandial responses of glucose, insulin, C-peptide, glucagon, proglucagon 1-61, active glucagon-
like peptide 1 (GLP-1), glicentin, oxyntomodulin and total peptide YY (PYY) during mixed meal test (MMT) in 
Roux-en-Y gastric bypass (RYGB)-operated participants (n = 8) before a diet-induced weight loss at ~3 months 
(MMT -3mo) and ~1 week (MMT -1wk) before surgery and ~1 week (MMT +1wk) and ~3 months (MMT 
+3mo) after surgery. Data are mean ± SD for normally distributed variables and medians with inter-quartile 
ranges in brackets for skewed distributions. Significant difference (false discovery rate-adjusted P < 0.1) 
between MMTs indicated by numerals in superscript. AUC, area under curve; bsAUC, baseline-subtracted 
AUC; Cmax, max concentration during MMT; Tmax, time-to-peak 
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